Fenretinide (4-HPR): A preventive chance for women at genetic and familial risk?

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The incidence and mortality of breast cancer have been recently influenced by several new therapeutic strategies. In particular our knowledge on cancer precursors, risk biomarkers, and genetics has considerably increased, and prevention strategies are being successfully explored. Since their discovery, retinoids, the natural and synthetic derivatives of vitamin A, have been known to play a crucial role in cell and tissue differentiation and their ability to inhibit carcinogenesis has made them the ideal chemopreventive agents studied in several preclinical and clinical trials. Fenretinide (4-HPR) is the most studied retinoid in breast cancer chemoprevention clinical trials due to its selective accumulation in breast tissue and its favorable toxicological profile. This agent showed a significative reduction of the incidence of second breast tumors in premenopausal women confirmed after 15-year followups. Considering Fenretinide protective action, a similar trend on ovarian cancer, this drug warrants reevaluations as a preventive agent for high-risk young women, such as BRCA-1 and 2 mutation carriers or with a high familial risk. This favorable effect therefore provides a strong rationale for a primary prevention trial in these unaffected cohort of women.

Original languageEnglish
Article number172897
JournalJournal of Biomedicine and Biotechnology
Volume2012
DOIs
Publication statusPublished - 2012

Fingerprint

Fenretinide
Retinoids
Breast Neoplasms
Clinical Trials
Incidence
Chemoprevention
Primary Prevention
Vitamin A
Ovarian Neoplasms
Toxicology
Cell Differentiation
Carcinogenesis
Breast
Biomarkers
Mutation
Mortality
Pharmaceutical Preparations
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Biotechnology
  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Health, Toxicology and Mutagenesis
  • Medicine(all)

Cite this

@article{d5a9980803e642b199a6feb625c74c18,
title = "Fenretinide (4-HPR): A preventive chance for women at genetic and familial risk?",
abstract = "The incidence and mortality of breast cancer have been recently influenced by several new therapeutic strategies. In particular our knowledge on cancer precursors, risk biomarkers, and genetics has considerably increased, and prevention strategies are being successfully explored. Since their discovery, retinoids, the natural and synthetic derivatives of vitamin A, have been known to play a crucial role in cell and tissue differentiation and their ability to inhibit carcinogenesis has made them the ideal chemopreventive agents studied in several preclinical and clinical trials. Fenretinide (4-HPR) is the most studied retinoid in breast cancer chemoprevention clinical trials due to its selective accumulation in breast tissue and its favorable toxicological profile. This agent showed a significative reduction of the incidence of second breast tumors in premenopausal women confirmed after 15-year followups. Considering Fenretinide protective action, a similar trend on ovarian cancer, this drug warrants reevaluations as a preventive agent for high-risk young women, such as BRCA-1 and 2 mutation carriers or with a high familial risk. This favorable effect therefore provides a strong rationale for a primary prevention trial in these unaffected cohort of women.",
author = "Massimiliano Cazzaniga and Clara Varricchio and Chiara Montefrancesco and Irene Feroce and Aliana Guerrieri-Gonzaga",
year = "2012",
doi = "10.1155/2012/172897",
language = "English",
volume = "2012",
journal = "Journal of Biomedicine and Biotechnology",
issn = "1110-7243",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Fenretinide (4-HPR)

T2 - A preventive chance for women at genetic and familial risk?

AU - Cazzaniga, Massimiliano

AU - Varricchio, Clara

AU - Montefrancesco, Chiara

AU - Feroce, Irene

AU - Guerrieri-Gonzaga, Aliana

PY - 2012

Y1 - 2012

N2 - The incidence and mortality of breast cancer have been recently influenced by several new therapeutic strategies. In particular our knowledge on cancer precursors, risk biomarkers, and genetics has considerably increased, and prevention strategies are being successfully explored. Since their discovery, retinoids, the natural and synthetic derivatives of vitamin A, have been known to play a crucial role in cell and tissue differentiation and their ability to inhibit carcinogenesis has made them the ideal chemopreventive agents studied in several preclinical and clinical trials. Fenretinide (4-HPR) is the most studied retinoid in breast cancer chemoprevention clinical trials due to its selective accumulation in breast tissue and its favorable toxicological profile. This agent showed a significative reduction of the incidence of second breast tumors in premenopausal women confirmed after 15-year followups. Considering Fenretinide protective action, a similar trend on ovarian cancer, this drug warrants reevaluations as a preventive agent for high-risk young women, such as BRCA-1 and 2 mutation carriers or with a high familial risk. This favorable effect therefore provides a strong rationale for a primary prevention trial in these unaffected cohort of women.

AB - The incidence and mortality of breast cancer have been recently influenced by several new therapeutic strategies. In particular our knowledge on cancer precursors, risk biomarkers, and genetics has considerably increased, and prevention strategies are being successfully explored. Since their discovery, retinoids, the natural and synthetic derivatives of vitamin A, have been known to play a crucial role in cell and tissue differentiation and their ability to inhibit carcinogenesis has made them the ideal chemopreventive agents studied in several preclinical and clinical trials. Fenretinide (4-HPR) is the most studied retinoid in breast cancer chemoprevention clinical trials due to its selective accumulation in breast tissue and its favorable toxicological profile. This agent showed a significative reduction of the incidence of second breast tumors in premenopausal women confirmed after 15-year followups. Considering Fenretinide protective action, a similar trend on ovarian cancer, this drug warrants reevaluations as a preventive agent for high-risk young women, such as BRCA-1 and 2 mutation carriers or with a high familial risk. This favorable effect therefore provides a strong rationale for a primary prevention trial in these unaffected cohort of women.

UR - http://www.scopus.com/inward/record.url?scp=84859731352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859731352&partnerID=8YFLogxK

U2 - 10.1155/2012/172897

DO - 10.1155/2012/172897

M3 - Article

C2 - 22500077

AN - SCOPUS:84859731352

VL - 2012

JO - Journal of Biomedicine and Biotechnology

JF - Journal of Biomedicine and Biotechnology

SN - 1110-7243

M1 - 172897

ER -